Clinical Trial Update: Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for GC012F CAR-T therapy targeting CD19 and BCMA in Chinese participants with relapsed or refractory AL amyloidosis, currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• GC012F

Snippet

Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. | Conditions: Relapsed/Refractory AL Amyloidosis | Phase 1 | Status: RECRUITING